The new guidance specifically applies to patients with a Psoriasis Area and Severity Index score of ten or more, a Dermatology Life Quality Index score of over ten, and who have not responded to or been able to receive other systemic treatments, including ciclosporin, methotrexate and phototherapy.
It is estimated that up to 1.8 million people in the UK are affected by some form of psoriasis, a life-long inflammatory condition that typically affects the skin, nails and joints.
Up to 90% of patients have plaque psoriasis, characterised by distinct round or oval plaques typically covered by silvery-white scales…
